Phytochemicals in Alzheimer Disease: The Development of Clinical Trials

Author： Quinn Joseph Kaye Jeffrey Montine Thomas Stackman Robert

ISSN： 1388-0209

Source： Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol.42, Iss.1, 2004-01, pp. : 64-73

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recruitment and Retention Strategies for Clinical Trials in Alzheimers Disease

By Sabbagh M.N.

Pharmaceutical Development and Regulation, Vol. 1, Iss. 4, 2003-01 ,pp. : 269-276

Adis International

Access to resources Recommend Favorite

Memantine for the Treatment of Alzheimer's Disease: Tolerability and Safety Data from Clinical Trials

By Farlow Martin R.

Drug Safety, Vol. 31, Iss. 7, 2008-01 ,pp. : 577-585

Adis International

Access to resources Recommend Favorite

Effects of Statins on Cognitive Function in Patients with Alzheimer's Disease in Galantamine Clinical Trials

By Winblad Bengt

Drugs & Aging, Vol. 24, Iss. 1, 2007-01 ,pp. : 57-61

Adis International

Access to resources Recommend Favorite

Drugs in Clinical Development for Alzheimer's Disease: Summary and Table†

Drugs & Aging, Vol. 29, Iss. 1, 2012-01 ,pp. : 73-79

Adis International

Access to resources Recommend Favorite

Drugs in Clinical Development for Alzheimer's Disease: Summary and Table

Pharmaceutical Medicine, Vol. 25, Iss. 1, 2011-02 ,pp. : 25-35

Adis International

Access to resources Recommend Favorite